Humacyte (HUMA) – Investment Analysts’ Recent Ratings Updates

Humacyte (NASDAQ: HUMA) recently received a number of ratings updates from brokerages and research firms:

  • 11/14/2026 – Humacyte was upgraded by Wall Street Zen to “sell”.
  • 11/12/2026 – Humacyte was given a new $1.00 price target by Cantor Fitzgerald.
  • 11/11/2026 – Humacyte had its price target raised by Barclays from $0.50 to $0.60. They now have an “equal weight” rating on the stock.
  • 11/10/2026 – Humacyte had its “buy” rating reaffirmed by BTIG Research. They now have a $2.00 price target on the stock.
  • 10/16/2026 – Humacyte was given a new $1.00 price target by Williams Trading.
  • 10/16/2026 – Humacyte had its “buy” rating reaffirmed by HC Wainwright.
  • 10/7/2026 – Humacyte was upgraded by Barclays to “hold”.
  • 10/6/2026 – Humacyte is now covered by Barclays. They set an “equal weight” rating and a $0.50 price target on the stock.
  • 10/2/2026 – Humacyte had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Humacyte Stock Performance

HUMA traded down $0.02 during mid-day trading on Monday, reaching $0.54. 3,044,061 shares of the company traded hands, compared to its average volume of 7,536,866. The company’s fifty day moving average price is $0.49 and its 200-day moving average price is $0.78. The stock has a market capitalization of $150.09 million, a P/E ratio of -1.23 and a beta of 2.64. The company has a quick ratio of 3.11, a current ratio of 3.34 and a debt-to-equity ratio of 3.65. Humacyte, Inc. has a 52-week low of $0.34 and a 52-week high of $1.52.

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Read More

Receive News & Ratings for Humacyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte Inc and related companies with MarketBeat.com's FREE daily email newsletter.